Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein.
The IGROVCDDP cisplatin-resistant ovarian cancer cell line is also resistant to paclitaxel and models the resistance phenotype of relapsed ovarian cancer patients after first-line platinum/taxane chemotherapy. A TaqMan low-density array (TLDA) was used to characterise the expression of 380 genes ass...
Main Authors: | Britta Stordal, Marion Hamon, Victoria McEneaney, Sandra Roche, Jean-Pierre Gillet, John J O'Leary, Michael Gottesman, Martin Clynes |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3394717?pdf=render |
Similar Items
-
Mitochondria P-glycoprotein confers paclitaxel resistance on ovarian cancer cells
by: Guo W, et al.
Published: (2019-05-01) -
Transcriptome Remodeling in Gradual Development of Inverse Resistance between Paclitaxel and Cisplatin in Ovarian Cancer Cells
by: Jolanta Szenajch, et al.
Published: (2020-12-01) -
Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin
by: Sherman-Baust Cheryl A, et al.
Published: (2011-12-01) -
No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin
by: Pinto Carla, et al.
Published: (2005-08-01) -
Clusterin Interacts with Paclitaxel and Confer Paclitaxel Resistance in Ovarian Cancer
by: Dong Choon Park, et al.
Published: (2008-09-01)